Clinical Trial Update: Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of RAD001 (everolimus) plus docetaxel in metastatic or recurrent non-small cell lung cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• RAD001 (everolimus)

Snippet

Sponsor: Emory University | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-05-28